Designed to scale into an end-to-end solution STABILITY can be used across a variety of healthcare settings and will include early warning systems for patient deterioration across several areas of care, including our existing STABILITY UO solution for Acute Kidney Injury, and our forthcoming Atrial Fibrillation solution.
Developed in collaboration with hospital researchers and clinical teams, STABILITY provides real-time monitoring and risk prediction analysis.Contact Us
Current early warning score models are limited by their use of generic thresholds. This often results in the subtle signs of patient deterioration being missed until it is too late to react. STABILITY anticipates patient deterioration before it occurs, improving patient safety and the timeliness of interventions.
STABILITY has the potential to make significant cost savings by reducing hospital length of stay and limiting unnecessary resource use.
STABILITY uses a patient’s physiological data and, therefore, each risk prediction score is entirely personalised.
STABILITY provides an easy to understand scoring system, promoting efficient assessment adoption. With automatic retrieval of data, the opportunities for incorrect data entry and subsequent calculations are significantly reduced.
STABILITY UO has been developed to predict the risk of developing AKI among patients in Critical Care Units, initially in patients who have undergone cardiac surgery. Powered by a clinically validated algorithm, STABILITY UO’s predictive power for AKI is better than any other predictive approaches currently available.
Using physiological measurements routinely taken in a hospital setting, STABILITY UO predicts the probability of a near-term episode of low urine output in time for preventive action to reduce the risk of AKI. Acute Kidney Injury (AKI) is a considerable healthcare burden and is estimated to cost the NHS alone between £434m and £620m per year. AKI is a common postoperative complication and occurs in up to 12% of patients in general undergoing surgical procedures and up to 34% of patients following cardiac surgery.
AKI is 100 times more deadly than MRSA, and the poor assessment of risk factors means that opportunities for prevention are often missed.